Deal Watch: Cancer Remains Hot Target At J.P. Morgan
Bluebird licenses Inhibrx’s single-domain antibody technology for use in constructs for CAR-T therapy generation. Jazz pays $56m up front under an engineered exosome collaboration with Codiak.
You may also be interested in...
Private Company Edition: Venture capital for emerging therapeutics companies in the US and in ex-US regions reached all-time highs in 2018. Also, Alphamab raises $60m Series B, three new VC funds launch and FLX changes its name to RAPT.
In a review of biopharma start-up dealmaking and financing activity from January through March, based on data from Strategic Transactions, Anthos completed the largest venture capital round in the first quarter, raising $250m.
With about three IPOs per month compared with a pace of nearly six per month in 2018, drug developers have raised $1.55bn with US offerings this year – though returns have been mixed.